Sacituzumab govitecan is comprised of a humanized antitrophoblast cell-surface antigen 2 monoclonal antibody coupled to SN-38 ...

Through a search of electronic health records from the IKnowMed clinical oncology database (McKesson, Houston, TX, USA) the ...

In recognition of September as Prostate Cancer Awareness Month, Daniel Petrylak, MD, professor of oncology and urology at ...

Plixorafenib (FORE 8394; PLX8394) with or without cobicistat (Tybost) demonstrated a clinical benefit and differentiated duration of response in patients with MAPK inhibitor-naive thyroid cancer ...

The FDA approved Bosaya and Aukelso biosimilars, enhancing options for cancer-related bone loss, including in patients with multiple myeloma. The FDA has approved Bosaya and Aukelso (denosumab-kyqq) ...

The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...

Cabozantinib, a tyrosine kinase inhibitor (TKI), was recently approved for patients with previously treated pancreatic NETs.

Ligufalimab receives FDA orphan drug designation for AML, showcasing promising efficacy and safety in treating hematologic ...

Researchers explore innovative macrocyclic peptides to target small cell lung cancer, revealing promising therapeutic ...

Kidney injury molecule–1 (KIM-1) has emerged as a potential prognostic biomarker for response to therapy and could be used to ...

The US FDA has granted breakthrough therapy designation to the novel antibody-drug conjugate (ADC) raludotatug deruxtecan ...

During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the ...